Press release
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size in the 7MM was ~USD 1,300 Million in 2023, estimated DelveInsight
DelveInsight's "Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Psychosis in Parkinson's and Alzheimer's Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson's and Alzheimer's Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Psychosis in Parkinson's and Alzheimer's Disease Market by downloading the comprehensive report from DelveInsight @ Psychosis in Parkinson's and Alzheimer's Disease Market [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Psychosis in Parkinson's and Alzheimer's Disease Market Report
* As per DelveInsight analysis, it is estimated that the Psychosis in Parkinson's and Alzheimer's Disease treatment market will experience significant changes during the forecast period of 2024-2034, owing to the launch of new therapies that are in clinical development for its treatment and due to the increasing patient pool.
* As per DelveInsight analysis, in 2023, there were approximately 15.4 million diagnosed prevalent cases of Alzheimer's disease in the 7MM. Out of these, the US accounted for approximately 41% of the total cases, while, the EU4 and the UK accounted for the least with nearly 33% of the total, in 2023.
* As per DelveInsight analysis, there were approximately 6 million total diagnosed prevalent cases of psychosis in Alzheimer's disease, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
* As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Parkinson's Disease Psychosis in the 7MM were approximately 876 thousand cases. These cases are projected to increase during the forecast period (2024-2034).
* The leading Psychosis in Parkinson's and Alzheimer's Disease Companies such as ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Promising Psychosis in Parkinson's and Alzheimer's Disease Therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
Gain a competitive edge in the Psychosis in Parkinson's and Alzheimer's Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Psychosis in Parkinson's and Alzheimer's Disease Treatment Drugs [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psychosis in Parkinson's and Alzheimer's Disease Epidemiology Segmentation in the 7MM
* Psychosis in Parkinson's and Alzheimer's Disease Diagnosed Prevalent Cases
* Psychosis in Parkinson's and Alzheimer's Disease Gender-specific Cases
* Psychosis in Parkinson's and Alzheimer's Disease Age-specific Cases
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market
The current treatment regime involves nonpharmacological and pharmacological approaches. The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. The use of typical and atypical antipsychotics are the first-line treatment (e.g., aripiprazole, clozapine, quetiapine, etc.). However, atypical antipsychotics are often considered in the initial therapy, which reduces the risk of later deterioration in patients. Apart from antipsychotics, 5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), or other antidepressants are also used.
Discover key developments and opportunities in the Psychosis in Parkinson's and Alzheimer's Disease Market. Click here to learn more from DelveInsight's latest report @ Psychosis in Parkinson's and Alzheimer's Disease Market Size [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psychosis in Parkinson's and Alzheimer's Disease Market Insights
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Psychosis in Parkinson's and Alzheimer's Disease Marketed Drugs
* NUPLAZID (pimavanserin): Acadia Pharmaceuticals
Psychosis in Parkinson's and Alzheimer's Disease Emerging Drugs
* Ulotaront (SEP-363856): Sunovion Pharmaceuticals
* KarXT (xanomeline-trospium): Karuna Therapeutics
* ITI-1284: Intra-Cellular Therapies
Psychosis in Parkinson's and Alzheimer's Disease Market Outlook
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Download DelveInsight's Psychosis in Parkinson's and Alzheimer's Disease Market report today and stay ahead in this rapidly evolving field. @ Psychosis in Parkinson's and Alzheimer's Disease Clinical Trials [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Psychosis in Parkinson's and Alzheimer's Disease Market Report
* Coverage- 7MM
* Psychosis in Parkinson's and Alzheimer's Disease Companies- ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
* Psychosis in Parkinson's and Alzheimer's Disease Therapies- NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
* Psychosis in Parkinson's and Alzheimer's Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Psychosis in Parkinson's and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement
Download the report to understand which factors are driving Psychosis in Parkinson's and Alzheimer's Disease Market Trends @ Psychosis in Parkinson's and Alzheimer's Disease Market Trends [https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Psychosis in PD and AD Market Overview at a Glance
4. Methodology of Psychosis in Parkinson's disease and Alzheimer's disease Epidemiology and Market
5. Executive Summary of Psychosis in Parkinson's disease and Alzheimer's disease
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Psychosis in Parkinson's disease and Alzheimer's disease: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psychosis-in-parkinsons-and-alzheimers-disease-treatment-market-size-in-the-7mm-was-usd-1300-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size in the 7MM was ~USD 1,300 Million in 2023, estimated DelveInsight here
News-ID: 3666596 • Views: …
More Releases from ABNewswire
Anwalt Zurich Launches as a New Law Firm in Zurich Providing Reliable Legal Coun …
A new Swiss law firm, Anwalt Zurich (https://anwalt-zuerich.legal/), has officially launched to provide professional legal advice and representation for private individuals and companies in Zurich and throughout Switzerland. The firm combines modern accessibility with traditional legal expertise, offering clients clear, pragmatic, and results-oriented counsel across a broad range of practice areas.
The launch of Anwalt Zurich, a new law firm in Zurich, responds to increasing demand for independent and locally focused…
Family-Run Jolly Co Creations Challenges Mass-Produced Kids' Fashion with Hometo …
Jolly Co Creations transforms authentic family moments into playful children's apparel, with designs created by their three boys, including their 7-year-old son. The Nebraska-based brand uses premium Bella + Canvas and Rabbit Skins fabrics, offering small-batch, ethically printed alternatives to mass-produced kids' fashion.
A Nebraska family has transformed everyday parenting moments into a thriving children's apparel business that celebrates authentic childhood experiences. Jolly Co Creations [https://jollycocreations.com], launched just six months ago,…
Vilva.ai Launches to End "Scattered Research" Chaos for Founders and Engineers
Vilva.ai is a new AI-powered knowledge platform which aims to eliminate cognitive overload, information fragmentation, and the synthesis gap for deep thinkers.
Image: https://www.abnewswire.com/upload/2025/11/f4e24521b440f39fe440d2cd39ffdd3e.jpg
Vilva.ai, an AI-native knowledge platform, officially launches today with a bold mission: to end the chaos of "scattered research" that plagues founders, product managers, and engineers working in tightly knit teams. Designed as a dynamic second brain for deep knowledge workers, Vilva.ai integrates the flexibility of visual whiteboarding…
Let Property Reviews: The UK's Leading Investment Property Marketplace Recognise …
Let Property wins national recognition after achieving exceptional verified reviews across Trustpilot, Google, and Feefo.
Glasgow, UK - 10 November, 2025 - Let Property, the UK's leading investment property marketplace, has been awarded the Top Rated Property Platform 2025 title following an in-depth review of verified customer feedback across multiple platforms.
According to the National Property Awards, Let Property has consistently demonstrated excellence in customer experience, transparent communication, and investor support -…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
